Therapeutic Asset Ratings
308 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Tsc-200-A0201
Melanoma
TScan Therapeutics, Inc.
P1
C
(37)
Tsc-201-B0702
Melanoma
TScan Therapeutics, Inc.
P1
C
(37)
Tsc-202-A0201
Melanoma
TScan Therapeutics, Inc.
P1
C
(37)
Tsc-203-A0201
Melanoma
TScan Therapeutics, Inc.
P1
C
(37)
Tsc-204-A0101
Melanoma
TScan Therapeutics, Inc.
P1
C
(37)
Tsc-204-A0201
Melanoma
TScan Therapeutics, Inc.
P1
C
(37)
Tsc-204-C0702
Melanoma
TScan Therapeutics, Inc.
P1
C
(37)
Vinorelbine
Melanoma
National Cancer Institute (NCI)
P1
C
(37)
INCB 086550
Melanoma
Incyte Corporation
P2
C
(36)
Cosibelimab
Melanoma
Checkpoint Therapeutics, Inc.
P1
C
(36)
IMMUNOGLOBULIN G1, ANTI-(HUMAN PROGRAMMED DEATH-LIGAND 1) (HUMAN MONOCLONAL STI-3031 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL STI-3031 .LAMBDA.-CHAIN, DIMER
Melanoma
Mayo Clinic
P1
C
(36)
msc1936369b
Melanoma
Day One Biopharmaceuticals, Inc.
P1
C
(36)
Polio Vaccine
Melanoma
Duke University
P1
C
(35)
Fosifloxuridine Nafalbenamide
Melanoma
NuCana plc
P1/2
C
(35)
Ex-Vivo Expanded Allogeneic Γδ T Cells
Melanoma
Xijing Hospital
Early P1
C
(34)
R130
Melanoma
Shanghai Yunying Medical Technology
Early P1
C
(34)
Recombinant L-Ifn Adenovirus
Melanoma
Shanghai Fengxian District Central Hospital
Early P1
C
(34)
atl001
Melanoma
Achilles Therapeutics UK Limited
P2
D
(30)
Milademetan
Melanoma
Rain Oncology Inc
P1/2
D
(30)
Incb099280
Melanoma
Incyte Corporation
P1
D
(29)
Sasanlimab
Melanoma
Pfizer
P1
D
(28)
124i-humanized 3f8
Melanoma
Memorial Sloan Kettering Cancer Center
N/A
D
(28)
18f-pfpn
Melanoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
D
(28)
99mTc-nanoscan
Melanoma
The Netherlands Cancer Institute
N/A
D
(28)
BLOOD, WHOLE
Melanoma
Mayo Clinic
D
(28)
Showing 276 to 300 of 308 assets
Previous
Page 12 of 13
Next
